Copyright
©The Author(s) 2022.
World J Hepatol. Jul 27, 2022; 14(7): 1277-1290
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1277
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1277
Table 1 Clinical studies investigating gut microbiota composition in patients with nonalcoholic fatty liver disease - induced hepatocellular carcinoma
Ref. | Participants (groups) | Exclusion criteria | Main findings | Other metabolites investigated |
Behary et al[19] | Patients with NAFLD-HCC-cirrhosis n = 32; Patients with NAFLD-cirrhosis n = 28; Control group (non-NAFLD) n = 30. | Unspecified | Subjects with NAFLD-HCC and NAFLD-cirrhosis had reduced α-diversity indices compared to non-NAFLD controls; NAFLD-HCC was characterized by expansion of Proteobacteria compared to a non-NAFLD group; Expansion of Enterobacteriaceae in NAFLD-HCC compared to NAFLD-cirrhosis and controls; NAFLD-HCC was characterized by a reduction in Oscillospiraceae and Erysipelotrichaceae compared to non-NAFLD; NAFLD-cirrhosis was characterized by an expansion of Eubacteriaceae compared to both NAFLD-HCC and controls; Bacteroides caecimuris and Veillonella parvula, were both significantly enriched in NAFLD-HCC, compared to NAFLD cirrhosis and controls | Pyruvate carboxylase (pycA), responsible for the production of oxaloacetate from pyruvate, was overexpressed in NAFLD-HCC compared to NAFLD-cirrhosis and non-NAFLD control; Genes related to acetate synthesis (phosphate acetyltransferase) and butyrate/acetyl phosphate synthesis (phosphate butyryltransferase) were both overexpressed in NAFLD-HCC compared to NAFLD cirrhosis and non-NAFLD controls; The feces of NAFLD-HCC subjects were enriched in acetate, butyrate and formate compared to NAFLD-cirrhosis and controls; Fecal SCFA was NAFLD-HCC specific |
Sydor et al[13] | Patients with NASH-non-HCC without cirrhosis n = 23; Patients with NASH-non-HCC with cirrhosis n = 11; Patients with NASH-HCC without cirrhosis n = 14; Patients with NASH-HCC with cirrhosis n = 19; Control group n = 20. | Unspecified | Bacteroidetes and, to a lesser extent, Actinobacteria were gradually decreased in abundance from controls to NASH-non-HCC to NASH-HCC; The abundance of Proteobacteria was significantly increased in NASH-HCC with cirrhosis; The abundances of Bacteroides and Bifidobacterium were decreased in NASH-non-HCC and NASH-HCC compared with controls; Lactobacillus showed a progressive increase in abundance from controls to NASH-HCC with cirrhosis; Abundance of Clostridium and Escherichia/Shigella remained unchanged; Lactobacillus-related ranks showed a progressive increase in abundance from controls to NASH-HCC with cirrhosis | Significant increase of BA associated with disease severity between healthy, NASH-non- HCC, and NASH-HCC; Individual and conjugated serum BA were associated with the abundance of Lactobacillus |
Ponziani et al[20] | Patients with NAFLD-HCC with cirrhosis n = 21; Patients with NAFLD-non-HCC with cirrhosis n = 20; Control group n = 20. | Patients with CVH, AH, cholestatic disorders such as PBC or PSC, and inherited liver disorders leading to cirrhosis such as hemochromatosis, Wilson's disease, and alpha-1 antitrypsin deficiency; Patients who were taking drugs such as antibiotics, probiotics, prebiotics, PPIs, and laxatives during the last 6 mo; affected by diseases potentially influencing the gut microbiota composition; Patients with a history of cancer. | α-diversity was less diverse in patients with cirrhosis compared to controls; Cirrhosis patients showed enriched Proteobacteria, Bacteroidetes and Cyanobacteria compared to healthy controls; The gut microbiota of the HCC group was enriched with Bacteroides, Ruminococcaceae, Enterococcus, Phascolarctobacterium, and Oscillospira compared to patients with cirrhosis but without HCC and controls; Reduced abundance of Verrucomicrobiaceae, Bifidobacteriaceae, Akkermansia, Bifidobacterium, Dialister, Collinsella, and Adlercreutzia were seen in NAFLD-HCC compared with NAFLD-non-HCC. | Intestinal permeability was increased in all patients with liver cirrhosis, who had higher levels of plasma ZO1 and LPS compared to controls |
- Citation: Liakina V, Strainiene S, Stundiene I, Maksimaityte V, Kazenaite E. Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis. World J Hepatol 2022; 14(7): 1277-1290
- URL: https://www.wjgnet.com/1948-5182/full/v14/i7/1277.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i7.1277